NASDAQ · XTLB
XTL Biopharmaceuticals financials
$2.21−0.90%
Close Sep 29, 2026 · split-adjustedXTL Biopharmaceuticals has no annual financial statements on file. Funds and some foreign issuers do not file them.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology